Clinical Trial Update: Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating adaptive androgen deprivation in combination with docetaxel for metastatic castration-sensitive prostate cancer; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-sensitive Prostate Cancer

Drugs mentioned

• Taxotere (docetaxel)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Metastatic Castration Sensitive Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING